/ 2 items

#SRPT↓

Featured/ SRPT/ 11/04/2025 · 5:37 AM

Sarepta Therapeutics Shares Crash 40% After Key Drug Trial Fails to Show Benefits

Sarepta Therapeutics stock plunges as confirmatory trial for DMD drugs misses primary endpoint, adding to company's recent setbacks including Elevidys safety concerns.

Featured/ SRPT/ 09/22/2025 · 5:56 AM

BMO Capital Upgrades Sarepta Stock Despite Concerns

BMO upgraded Sarepta stock, seeing high rewards despite drug safety worries. Elevidys sales are spiking, likely beating expectations. Future projects will bring new investors.